List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 21 studies with search of: everolimus and solid tumors | Open Studies
Include studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting SORAVE - Sorafenib and Everolimus in Solid Tumors
Condition: Relapsed and/or Refractory Solid Tumors
Intervention: Drug: Combination of sorafenib and everolimus
2 Recruiting BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
Condition: Solid Tumors
Intervention: Drug: bevacizumab, everolimus, panitumumab
3 Recruiting Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Head and Neck Cancer;   Islet Cell Tumor;   Kidney Cancer;   Lung Cancer;   Malignant Paraganglioma;   Melanoma (Skin);   Neuroendocrine Carcinoma of the Skin;   Pheochromocytoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib;   Genetic: protein expression analysis;   Other: high performance liquid chromatography;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: ultrasound imaging
4 Recruiting A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors
Conditions: Recurrent or Refractory Solid Tumors;   CNS Malignancies
Interventions: Drug: Bevacizumab;   Drug: Everolimus
5 Not yet recruiting Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: Bevacizumab, Everolimus and LBH589
6 Not yet recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer
Condition: Advanced Solid Tumors
Intervention: Drug: AMG 479, Everolimus, Panitumumab
7 Recruiting A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
Conditions: Non-small Cell Lung Cancer;   Pancreatic Cancer;   Solid Tumors
Intervention: Drug: GSK1120212 plus everolimus
8 Not yet recruiting Everolimus and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: gemcitabine hydrochloride
9 Recruiting Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: panitumumab;   Drug: everolimus;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
10 Recruiting Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer;   Advanced Solid Tumors;   Cancer;   Gastrointestinal Disease;   Rectal Disease
Interventions: Drug: capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev);   Drug: bevacizumab/capecitabine/oxaliplatin (XELOX-A)
11 Recruiting A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors
Condition: Neoplasms
Interventions: Drug: R1507;   Drug: RAD001
12 Recruiting RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms
Conditions: Sarcoma;   Solid Tumor
Interventions: Drug: RAD001;   Drug: CP-751,871
13 Recruiting A Study of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (P04722)
Condition: Neoplasms
Interventions: Drug: Regimen A: FOLFIRI (± Cetuximab), and SCH 717454;   Drug: Regimen B: Carboplatin, Paclitaxel, and SCH 717454;   Drug: Regimen C: Epirubicin, Cisplatin, 5-FU, and SCH 717454;   Drug: Regimen D: Trastuzumab and SCH 717454;   Drug: Regimen E: mTor Inhibitor (Everolimus) and SCH 717454;   Drug: Regimen F: Gemcitabine (± Erlotinib), and SCH 717454
14 Recruiting Phase I Study of Patupilone and RAD001
Condition: Refractory Malignancy
Interventions: Drug: Patupilone;   Drug: RAD001
15 Not yet recruiting A Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Condition: Colorectal Cancer
Interventions: Drug: RAD011;   Drug: FOLFOX;   Drug: Bevacizumab
16 Recruiting Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RADOO1
Condition: Kidney Neoplasms
Interventions: Drug: RAD001 (Certican);   Drug: bevacizumab
17 Recruiting Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
Condition: Endometrial Cancer
Interventions: Drug: Topotecan;   Drug: RAD001
18 Recruiting Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
Condition: Breast Cancer
Interventions: Drug: Capecitabine;   Drug: RAD001
19 Recruiting VEGF Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma
Conditions: Metastatic Renal Cell Carcinoma;   Everolimus Treatment
Intervention: Other: 89Zr-bevacizumab PET scan
20 Recruiting RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: RAD001;   Drug: PKC412

Previous Page Studies Shown (1-20) Next Page (21-21)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services